This study portends a great resource for Sulfinpyrazone site future research. Future research could explore technological solutions and options that could strengthen excavation works for buried utilities. The current analysis has focused on the improvement of asbuilt records from a method viewpoint. Lastly, this study is restricted by its sample size because the survey was undertaken during COVID19 lockdowns. Hence, a lot more empirical research are encouraged across New Zealand projects to extend the current findings. By way of example, financial considerations in future research might aid to buttress the primacy of asbuilt records as a costsaving measure in underground utility operations.Author Contributions: Conceptualization, S.M.; methodology, S.M. and J.O.B.R.; validation, S.M.; formal evaluation, S.M.; investigation, S.M.; information curation, F.E.R. and J.O.B.R.; writingoriginal draft preparation, S.M., F.E.R. and J.O.B.R.; writingreview and editing, S.M., F.E.R. and J.O.B.R.; visualization, S.M., F.E.R. and J.O.B.R.; supervision, J.O.B.R.; project administration, F.E.R.; funding acquisition, J.O.B.R. All authors have study and agreed to the published version from the manuscript. Funding: The APC was funded by the Productivity in Built Environment study group, School of Constructed Environment, Massey University, New Zealand. Institutional Assessment Board Statement: The study was conducted as outlined by the guidelines and Lufenuron Biological Activity approval provided by the Human Ethics Committee of Massey University (notification number 4000022572). Informed Consent Statement: Informed consent was obtained from all subjects involved in the study. Information Availability Statement: The data presented within this study are obtainable on request from the corresponding author. Conflicts of Interest: The authors declare no conflict of interest.
cancersArticleThe Synergistic AntiTumor Activity of EZH2 Inhibitor SHR2554 and HDAC Inhibitor Chidamide through ORC1 Reduction of DNA Replication Method in Diffuse Big B Cell LymphomaXing Wang 1, , Dedao Wang 1, , Ning Ding 1 , Lan Mi 1 , Hui Yu 1 , Meng Wu 1 , Feier Feng 1 , Luni Hu 2 , Yime Zhang 2 , Chao Zhong two , Yingying Ye 1 , Jiao Li 1 , Wei Fang 1 , Yunfei Shi 3 , Lijuan Deng 1 , Zhitao Ying 1 , Yuqin Song 1, and Jun Zhu 1, Citation: Wang, X.; Wang, D.; Ding, N.; Mi, L.; Yu, H.; Wu, M.; Feng, F.; Hu, L.; Zhang, Y.; Zhong, C.; et al. The Synergistic AntiTumor Activity of EZH2 Inhibitor SHR2554 and HDAC Inhibitor Chidamide via ORC1 Reduction of DNA Replication Process in Diffuse Substantial B Cell Lymphoma. Cancers 2021, 13, 4249. https://doi.org/10.3390/ cancers13174249 Academic Editor: Samuel C. Mok Received: 13 Might 2021 Accepted: 28 July 2021 Published: 24 AugustKey Laboratory of Carcinogenesis and Translational Analysis (Ministry of Education), Division of Lymphoma, Peking University Cancer Hospital Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China; [email protected] (X.W.); [email protected] (D.W.); [email protected] (N.D.); [email protected] (L.M.); [email protected] (H.Y.); [email protected] (M.W.); [email protected] (F.F.); [email protected] (Y.Y.); [email protected] (J.L.); [email protected] (W.F.); [email protected] (L.D.); [email protected] (Z.Y.) Institute of Systems Biomedicine, Department of Immunology, Beijing Essential Laboratory of Tumor Systems Biology, Peking University Health Science Center, Beijing 100191, China; [email protected] (L.H.); [email protected] (Y.Z.); [email protected] (C.Z.).